Article

Dissection of demethylation and toxicity induced gene expression changes after decitabine treatment

2019-12-19

Abstract excerpt

The DNA methyltransferase inhibitor decitabine (DAC) is a widely used drug for both fundamental epigenetics studies and anti-cancer therapy. Besides DNA demethylation, DAC also induces cell toxicity associated with DNA damage. The dual-mode of DAC action on cells provides a significant hurdle to study genes which expression is regulated by CpG methylation. In this work, we performed the analysis of global DNA meth...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: cf9aa83b-22f7-5ab6-9074-f5b890296173
DOI: 10.1101/2019.12.18.880633

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Dissection of demethylation and toxicity induced gene expression changes after decitabine treatmentDOI 10.1101/2019.12.18.880633Read

Effects of 5-Aza-2′-deoxycytidine (decitabine) on gene expressionSemantic proximity Read

Recurrent transcriptional responses in AML and MDS patients treated with decitabineSemantic proximity Read

[The Epigenetic Regulation of Decitabine Resistance in TP53 -Mutated Myelodysplastic Syndromes: Integrated Analysis Based on RNA-seq and Methylomics].Semantic proximity Read

Integrated Epigenetics of Human Breast Cancer: Synoptic Investigation of Targeted Genes, MicroRNAs and Proteins upon Demethylation TreatmentSemantic proximity Read

Decitabine and its role in the treatment of hematopoietic malignanciesSemantic proximity Read

Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemiaSemantic proximity Read

Decitabine-induced DNA methylation-mediated transcriptomic reprogramming in human breast cancer cell lines; the impact of DCK overexpressionSemantic proximity Read

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell lineSemantic proximity Read

p53 status determines the epigenetic response to demethylating agents Azacitidine and DecitabineSemantic proximity Read

Genomic impact of transient low-dose decitabine treatment on primary AML cellsSemantic proximity Read

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell lineSemantic proximity Read

Decitabine treatment demethylates vast majority of high-confidence differentially methylated regions in HCT-116 colorectal cancer cellsSemantic proximity Read